My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

182.04 +1.29 (+0.71%)

Streaming Delayed Price Updated: 12:41 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

56 57 Next >

Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024

October 22, 2024

From Biogen Inc.

Via GlobeNewswire

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce ↗

October 17, 2024

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and...

Via Benzinga

Topics Workforce

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock ↗

October 16, 2024

Oppenheimer has initiated coverage on Larimar Therapeutics, emphasizing its lead program Nomlabofusp as a transformative therapy for Friedreich's ataxia. With a price target of $26, the company plans...

Via Benzinga

Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe ↗

October 14, 2024

Eli Lilly invests £279M in the UK to boost life sciences, while its Alzheimer's drug, donanemab, faces European regulatory hurdles amid ongoing trials and safety concerns.

Via Benzinga

The Latest Analyst Ratings For Biogen ↗

October 10, 2024

Via Benzinga

Looking Into Biogen's Recent Short Interest ↗

October 03, 2024

Via Benzinga

Forecasting The Future: 20 Analyst Projections For Biogen ↗

September 23, 2024

Via Benzinga

Large-Cap Stocks In Trouble - Sunday, Oct. 13 ↗

October 13, 2024

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.

Via Talk Markets

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

October 10, 2024

Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays.

Via MarketBeat

Topics ETFs Earnings

Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients

October 09, 2024

From Biogen Inc.

Via GlobeNewswire

Key Takeaways From Biogen Analyst Ratings ↗

September 04, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Biogen ↗

August 19, 2024

Via Benzinga

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study ↗

October 08, 2024

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.

Via Benzinga

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

October 08, 2024

From Biogen Inc.

Via GlobeNewswire

Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year ↗

October 07, 2024

Scholar Rock's Phase 3 SAPPHIRE trial for apitegromab in spinal muscular atrophy met its primary endpoint, showing statistically significant motor function improvements and favorable outcomes compared...

Via Benzinga

1 Unstoppable Growth Stock Heading to $2 Trillion by 2030 ↗

September 28, 2024

It's hard to bet against this company right now.

Via The Motley Fool

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate ↗

September 26, 2024

Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February...

Via Benzinga

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial ↗

September 24, 2024

UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48...

Via Benzinga

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

September 24, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen Board Appoints Two New Independent Directors

September 12, 2024

Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development

From Biogen Inc.

Via GlobeNewswire

Zepbound And Mounjaro Maker Eli Illy Has A New CFO As It Navigates Regulatory Challenges: What You Should Know ↗

September 09, 2024

Eli Lilly and Company has appointed Lucas Montarce as executive vice president and chief financial officer, effective immediately.

Via Benzinga

Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗

September 09, 2024

Via Benzinga

Biogen/Eisai's Leqembi Brings Hope To Early Alzheimer's Patients Amid Logistical Challenges ↗

September 09, 2024

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the benefits, but challenges with side effects, insurance, and diagnostics...

Via Benzinga

Biogen's Higher Dose Spinraza Shows To Slow Neurodegeneration Faster In Infants With Rare Neuromuscular Disorder ↗

September 04, 2024

Biogen announced topline data from the Phase 2/3 DEVOTE study showing a higher dose of nusinersen significantly improves motor function in treatment-naïve infants with spinal muscular atrophy, compared...

Via Benzinga

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 04, 2024

From Biogen Inc.

Via GlobeNewswire

These 3 Factors Could Make Eli Lilly Stock a Better Buy Than Novo Nordisk Right Now ↗

August 31, 2024

This competitive showdown just saw one of the players hit a couple of bumps.

Via The Motley Fool

Eli Lilly Is The Nvidia Of Weight Loss And GLP-1 Space, Says Roundhill Investments CEO, Emphasizes Market Leadership And Growth Potential Of Zepbound Maker ↗

August 28, 2024

Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.

Via Benzinga

Chinese E-Commerce Giant Drops 35% In 2 Days, But Analysts See 92% Upside Potential ↗

August 27, 2024

PDD Holdings Inc. (NASDAQ: PDD) saw a 29% drop after disappointing Q2 results, but analysts remain bullish with price targets ranging from $84 to $185.

Via Benzinga

Eli Lilly's Alzheimer's Drug Faces UK Agency Block After Biogen's Medicine Rejection Over Cost, Safety ↗

August 26, 2024

The NHS is expected to block the Alzheimer's drug donanemab due to safety risks and high costs following NICE's recent rejection of Biogen's lecanemab, leaving campaigners and experts disappointed.

Via Benzinga

Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement ↗

August 22, 2024

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.